This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Santa Barbara-based biotech firm CytomX Therapeutics has raised $30 million in venture capital and announced plans to move to the San Francisco Bay Area by the end of the year. The company is developing technology that would help antibodies better target the disease tissue they’re intended for, reducing harmful side effects. It was founded by Read More →